ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Birmingham, AL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Ovarian Cancer
Cancer
Colorectal Cancer
Endometrial Cancer

Triple Negative Breast Cancer trials near Birmingham, AL, USA:

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe)

avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage I...

Active, not recruiting
Stage IIIA Breast Cancer
Recurrent Breast Carcinoma
Biological: Utomilumab
Biological: Anti-OX40 Antibody PF-04518600

Phase 2

Laura Huppert, MD, BA

Birmingham, Alabama, United States and 11 other locations

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Birmingham, Alabama, United States of America and 372 other locations

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple...

Active, not recruiting
Metastatic Triple Negative Breast Cancer
Drug: Olaparib Continuous (28-Day cycle) 300 mg BD.
Drug: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).

Phase 2

AstraZeneca
AstraZeneca

Birmingham, Alabama, United States and 140 other locations

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estro ...

Enrolling
Metastatic Breast Cancer
Drug: Mifepristone
Drug: Enzalutamide

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Birmingham, Alabama, United States and 11 other locations

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (B ...

Enrolling
HR+/HER2- Ductal and Lobular Breast Cancer
Non-small Cell Lung Cancer
Drug: [68Ga]Ga-NNS309
Drug: [177Lu]Lu-NNS309

Phase 1

Novartis
Novartis

Birmingham, Alabama, United States and 28 other locations

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

besides treating your disease.Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed w...

Enrolling
Endometrial Cancer
Gastric Cancer
Drug: pembrolizumab
Drug: PF-08046054

Phase 1

Seagen, a wholly owned subsidiary of Pfizer

Birmingham, Alabama, United States and 61 other locations

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult particip...

Enrolling
Breast Cancer
Lung Cancer
Drug: Pembrolizumab
Drug: BMS-986507

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Birmingham, Alabama, United States and 64 other locations

PRE-ISPY Phase I/II Oncology Platform Program

moving promising drug regimens into a larger phase II (or III) trial and in general could feed the neoadjuvant breast I-SPY 2 Trial (NCT010...

Enrolling
Colon Cancer
Colo-rectal Cancer
Drug: Fam-Trastuzumab Deruxtecan-Nxki
Drug: TTX-MC138

Phase 1, Phase 2

QuantumLeap Healthcare Collaborative

Birmingham, Alabama, United States and 9 other locations

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (SOLARA)

followed by immunotherapy, for patients with brain metastases from triple negative or BRCA-mutated breast cancers...

Active, not recruiting
Breast Cancer
Brain Metastases, Adult
Drug: Durvalumab
Radiation: Stereotactic Radiosurgery

Phase 1, Phase 2

Colette Shen

Birmingham, Alabama, United States and 6 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems